Pivotal Randomized Open-label Study of Optune (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM

  • End date
    Aug 2, 2026
  • participants needed
  • sponsor
    NovoCure GmbH
Updated on 2 September 2021
Leonardo Lustgarten, MD
Primary Contact
Highland Oncology Group (1.2 mi away) Contact
+161 other location
karnofsky performance status
complete resection
tumor progression
gross total resection
tumor treating fields therapy


To test the effectiveness and safety of Optune given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune and maintenance temozolomide are continued following radiation therapy.


Optune is a medical device that has been approved for the treatment of recurrent and newly diagnosed glioblastoma (GBM) by the Food and Drug Administration (FDA) in the United States. Optune has obtained a CE mark in Europe for recurrent and newly diagnosed GBM.

The current standard of care for GBM includes the addition of Optune to maintenance temozolomide (TMZ), following the completion of radiation therapy (RT).

The purpose of the current study is to test if the earlier introduction of Optune, at the time of radiation therapy (which is given together with temozolomide), improves clinical outcomes compared to the standard of care.

The study will randomize 950 subjects equally to one of two treatment arms:

  1. Treatment arm I: Patients receive TTFields at 200 kHz to the brain using the Optune System together with RT and TMZ, followed by maintenance TMZ concomitant with the Optune treatment.
  2. Treatment arm II: Patients receive RT and TMZ alone, followed by maintenance TMZ concomitant with TTFields at 200 kHz to the brain using the Optune.

All patients are to receive standard RT and TMZ treatment followed by maintenance TMZ chemotherapy and Optune according to the current standard of care regimen.

Optune will continue until second disease progression per RANO Criteria or 24 months (the earlier of the two) unless any of the treatment discontinuation conditions described under criteria for patient withdrawal or termination are met.

After surgery or biopsy, subjects that would like to participate will be required to submit samples of their tumor to a lab for testing. The results of this test will be used for randomization into the trial.

If the subject is assigned to the treatment group that will start Optune therapy during radiation therapy, Optune therapy will begin within 7 days of enrolling in the study and no later than the first day of RT and TMZ treatment.

After the initial visit, subjects will continue treatment at home, while pursuing normal daily routines. Subjects are required to use the device for at least 18 hours a day. Short breaks in treatment for personal hygiene and other personal needs is allowed. Total usage time will be recorded and provided to the sponsor.

Subjects will be required to return to the clinic every 4 weeks until study participation ends. Once every 8 weeks until the tumor potentially returns twice, subjects will have a contrast MRI of the head and neurological exam performed for the first 6 months of the study and then at least every three months until a total time period of 24 months.Once every 12 weeks until second disease progression, subjects will also fill out a quality of life questionnaire.

After the second time the tumor returns, subjects will return to the clinic for one final visit approximately 30 days after the last treatment with Optune.

After discontinuing Optune subjects will be contacted once per month by telephone to answer basic questions about their health status.

Condition Glioblastoma Multiforme, glioblastoma
Treatment Optune®
Clinical Study IdentifierNCT04471844
SponsorNovoCure GmbH
Last Modified on2 September 2021


Yes No Not Sure

Inclusion Criteria

Histologically confirmed diagnosis of GBM according to WHO classification criteria
Age 22 years in US and Age 18 years in Ex-US
Recovered from maximal debulking surgery, if applicable (gross total resection, partial resection, and biopsy-only patients are all acceptable)
Planned treatment with RT/TMZ followed by TTFields and maintenance TMZ (150-200 mg/m2 daily x 5 d, q28 days)
Karnofsky performance status 70
Life expectancy least 3 months
Participants of childbearing age must use highly effective contraception. An effective method of birth control is defined as one that results in a failure rate of less than 1% per year when used consistently and correctly. The Investigator must approve the selected method, and may consult with a gynecologist as needed
All patients must understand and voluntarily sign an informed consent document prior to any study related assessments/procedures being conducted
Stable or decreasing dose of corticosteroids for the last 7 days prior to randomization, if applicable
Concomitant RT with TMZ treatment planned to start no later than 8 weeks from surgery
Women of childbearing potential must have a negative -HCG pregnancy test documented within 14 days prior to registration
Is able to have MRI with contrast of the brain

Exclusion Criteria

Progressive disease (per investigator's assessment)
Infratentorial or leptomeningeal disease
Participation in another clinical treatment study during the pre-treatment and/or the treatment phase of the study
Pregnancy or breast-feeding
Significant co-morbidities at baseline which would preclude maintenance RT or TMZ treatment, as determined by the investigator
Thrombocytopenia (platelet count < 100 x 103/L)
Neutropenia (absolute neutrophil count < 1.5 x 103/L)
CTC grade 4 non-hematological Toxicity (except for alopecia, nausea, vomiting)
Significant liver function impairment - AST or ALT > 3 times the upper limit of normal
Total bilirubin > 1.5 x upper limit of normal
Significant renal impairment (serum creatinine > 1.7 mg/dL, or > 150 mol/l)
History of any psychiatric condition that might impair patient's ability to understand or comply with the requirements of the study or to provide consent
Implanted pacemaker, defibrillator, deep brain stimulator, other implanted electronic devices in the brain, or documented clinically significant arrhythmias
Evidence of increased intracranial pressure (midline shift > 5mm, clinically significant papilledema, vomiting and nausea or reduced level of consciousness)
History of hypersensitivity reaction to TMZ or a history of hypersensitivity to DTIC
Any other cytotoxic or biologic anti-tumor therapy received prior to enrollment will be considered exclusion
Admitted to an institution by administrative or court order
Known allergies to medical adhesives or hydrogel
A skull defect (such as, missing bone with no replacement)
Prior radiation treatment to the brain for the treatment of GBM
Any serious surgical/post-operative condition that may risk the patient according to the investigator
Standard TTFields exclusion criteria include
Active implanted medical devices
Bullet fragments
Skull defects
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note